KEKerem Erdoğan

Kerem Erdoğan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kerem Erdoğan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Endocannabinoid System in Allergic Airway Diseases: Mechanisms and Therapeutic Potential

    by Gaye Öztürk, Tülay Özge Alpaslan, Kerem Erdoğan, Emrah Bozkurt

    Allergic airway diseases, including allergic asthma and rhinitis, are characterised by airway inflammation and altered responses to inhaled allergens. The endocannabinoid system (ECS) significantly contributes to the regulation of airway tone and immune system activity. Experimental studies indicate that cannabinoid receptor ligands and inhibitors of endocannabinoid metabolism can modify airway hyperreactivity, inflammatory cell recruitment, and allergic inflammation. However, these effects are not uniform. CB1 and CB2 receptor signalling may produce different outcomes depending on the ligand, responding cell population, tissue, and experimental model. Endocannabinoid-related lipids may likewise exert protective or pro-inflammatory effects through different pathways. Evidence for therapeutic targeting of the ECS is more extensive in allergic asthma, where improvements in airway function or inflammation have been reported. In allergic rhinitis, pharmacological evidence remains limited, and the available clinical findings are insufficient to draw definitive conclusions. The established data suggests the ECS as a potential target in allergic airway diseases while underscoring the need to clarify receptor-dependent and receptor-independent mechanisms mediating their effects and establish efficacy and safety in well-characterized human populations. This review focuses on the role of the ECS in allergic airway diseases and evaluates its potential as a therapeutic target.